Santini Valeria, Prebet Thomas, Fenaux Pierre, Gattermann Norbert, Nilsson Lars, Pfeilstöcker Michael, Vyas Paresh, List Alan F
University of Florence, Florence, Italy.
Département d'Hématologie, Centre de recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France.
Leuk Res. 2014 Dec;38(12):1381-91. doi: 10.1016/j.leukres.2014.09.008. Epub 2014 Sep 22.
In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss of response or progression on azacitidine. In addition, we briefly consider optimization of first-line treatment along with potential biomarkers for identifying and monitoring response during treatment with azacitidine.
在欧洲，阿扎胞苷是唯一被批准用于治疗国际预后评分系统（IPSS）2级/高危骨髓增生异常综合征患者的去甲基化药物，与传统治疗相比，其显著提高了生存率。然而，并非所有接受阿扎胞苷治疗的患者都对治疗有反应，而且绝大多数有反应的患者随后会复发。目前，对于阿扎胞苷治疗失败后的患者尚未确立标准治疗方案。在此，我们讨论阿扎胞苷治疗反应丧失或病情进展后的治疗选择。此外，我们简要考虑一线治疗的优化以及在阿扎胞苷治疗期间用于识别和监测反应的潜在生物标志物。
